Share

July 2020; 7 (4) EditorialOpen Access

Are aquaporin antibody titers useful outcome measures for neuromyelitis optica spectrum disorders?

Markus Reindl
First published May 28, 2020, DOI: https://doi.org/10.1212/NXI.0000000000000759
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
456

Share

Article Information

vol. 7 no. 4 e759
DOI: 
https://doi.org/10.1212/NXI.0000000000000759
PubMed: 
33306483
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received April 8, 2020
  • Accepted in final form April 17, 2020
  • First Published May 28, 2020.
Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Markus Reindl, PhD
  1. Markus Reindl, PhD
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. PLOS ONE, academic editor, 2012,

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. The University Hospital and Medical University of Innsbruck (Austria, Markus Reindl) receive payments for antibody assays (NMDAR, AQP4 and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Luebeck, Germany).

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Euroimmun AG, Germany

    Research Support, Government Entities:

    1. (1) Austrian Science Funds (FWF), project P32699, PI, 2019-2022 (2) Austrian Federal Ministry of Science, Research and Education, grant BIG WIG MS, PI, 2013-2017 (3) Austrian Research promotion Agency (FFG), Bridge 1 project Nr. 853209, PI, 2016-2018 (4) Austrian Science Funds (FWF), project W1206, PI, 2007-2018 (5), Austrian Science Funds (FWF), project ZFP326990, PI, 2019-2022

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Clinical Department of Neurology, Medical University of Innsbruck, Austria.
  1. Correspondence
    Dr. Reindl markus.reindl{at}i-med.ac.at
View Full Text

Article usage

Article usage: May 2020 to December 2021

AbstractFullPdfSource
May 202005217Highwire
Jun 2020109141Highwire
Jul 2020633877Highwire
Aug 202065016Highwire
Sep 20203789Highwire
Oct 202064218Highwire
Nov 20201307Highwire
Dec 202035929Highwire
Jan 202144831Highwire
Feb 202122415Highwire
Mar 202114117Highwire
Apr 202102017Highwire
May 202113424Highwire
Jun 202103614Highwire
Jul 202122527Highwire
Aug 202102418Highwire
Sep 20210179Highwire
Oct 202113132Highwire
Nov 202112232Highwire
Dec 20210266Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

Alert Me

Advertisement